Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2006

Lonza and Bio*One Capital Invest $350M in Singapore Manufacturing Plant

  • Lonza and Bio*One Capital will build a large-scale mammalian cell culture facility in Singapore to manufacture commercial biopharmaceuticals, under a new joint venture, Lonza Biologics Tuas. Depending upon customer request, Lonza anticipates the capital investment will amount up to $350 million. This will be the second large-scale mammalian manufacturing plant in Singapore and the third one globally that Lonza has built.

    Lonza Biologics Tuas, located in Tuas Biomedical Park, will have up to four mammalian bioreactor trains. Each will have a flexible capacity of 1,000 up to 20,000 liters inclusive of the respective purification units. Lonza expects the facility to become operational latest by 2011.

    The 80,000-liter large-scale mammalian biopharmaceutical production facility to be built under the February 2006 joint venture between the two companies is now completely owned by Lonza, according to the Lonza Biologics Tuas joint venture. Genentech holds the exclusive option to acquire the Lonza-owned facility, which is producing the company’s cancer drug Avastin, between 2007 and 2012.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »